Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether the combination treatment of Paclitaxel and
Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will
generate better clinical response than Paclitaxel alone.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health